Core Viewpoint - Century Therapeutics, Inc. has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for Century Therapeutics indicates an expected loss of -$1.70 per share for the fiscal year ending December 2024, reflecting a year-over-year change of 18.3% [9]. - Over the past three months, analysts have raised their earnings estimates for Century Therapeutics by 8.5% [9]. Zacks Rating System - The Zacks rating system is based on changes in a company's earnings picture, which is crucial for stock price movements [2][3]. - The system classifies stocks into five groups, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [8]. - Only the top 20% of Zacks-covered stocks receive a 'Strong Buy' or 'Buy' rating, indicating superior earnings estimate revisions [10][11]. Market Implications - The upgrade to Zacks Rank 2 positions Century Therapeutics in the top 20% of stocks covered by Zacks, suggesting potential for market-beating returns in the near term [11]. - Rising earnings estimates and the corresponding rating upgrade signal an improvement in the company's underlying business, likely leading to increased stock price [6].
What Makes Century Therapeutics (IPSC) a New Buy Stock